HealthTech Arkansas announces new accelerator focused on biotherapeutic start-ups
HealthTech Arkansas and SymBiosis Capital Management have joined forces to create “BioAR Trial,” an accelerator program to help biotherapeutics companies in late pre-clinical stages of development bring groundbreaking therapies to market faster, while increasing Arkansans’ access to cutting-edge clinical care and innovative medicines.
According to this news release, companies from around the world are invited to apply to participate in the accelerator which will focus on deploying advanced and emerging therapeutic modalities – precision medicines, biologics, cell therapies, and genetic medicines – to treat serious and life-threatening diseases in oncology, immune disorders, and cardio-metabolic disease.
Applications are being accepted through January 15 at bioarkansas.co, and the first cohort of five companies will begin in April 2023. Partner hospitals and health systems are: (1) Arkansas Children’s Research Institute; (2) Arkansas Heart Hospital; (3) Baptist Health; (4) CHI St. Vincent; (5) Highlands Oncology Group; (6) St. Bernards Healthcare; and (7) University of Arkansas for Medical Sciences.
Just ahead of the announcement of “BioAR Trial,” HealthTech Arkansas and MedAxiom announced participants in “HeartX,” a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early stage companies bringing new cardiovascular innovations to market. Many of the same healthcare providers are involved in this program.
